Microbot Medical ($MBOT): Can LIBERTY Turn Repeat Orders into Growth?

01 Scenarios: can repeat procedures turn a launch into a business?

Microbot Medical has crossed the initial regulatory and commercial thresholds for LIBERTY. The question now is whether hospitals will adopt the disposable robotic system repeatedly, at an economic cost of production. The full U.S. commercial launch occurred on April 13, 2026; second-quarter revenue reached $241,000, while product costs were $884,000. Cash and money-market securities totaled a calculated $67.367 million at June 30, 2026. Those resources support expansion, but commercial success still requires substantially more revenue and better unit economics. Source Source

Bull case

The constructive scenario requires customers to move from initial evaluations to recurring procedures, with higher production volumes reducing the cost per system. Microbot’s September 25, 2026 update describes its first California customer, expansion into North Carolina and a target of twelve U.S. sales territories by year-end. If the wider coverage produces repeat orders rather than simply more evaluations, the commercial launch could develop into a more durable revenue stream. Management’s positive-gross-margin target for 2027 would become more credible as manufacturing performance improves. These are conditions for the favorable case, not outcomes already achieved. Source

The attraction is the combination of an already cleared peripheral-intervention product and a cash reserve that allows commercial learning. Hospitals do not need the same large capital purchase associated with some traditional robotic platforms. That can help adoption, although approval by hospital purchasing committees still takes time. A better result would combine broader use within existing accounts, a shorter path from evaluation to orders and less cash absorbed per increment of sales. Revenue growth alone would establish only part of that progression.

Base case

The central scenario is a funded early launch with uneven quarterly progress. The September 25, 2026 update puts the hospital Value Analysis Committee process at approximately four to six months in the company’s experience. A territory opened near year-end may therefore contribute limited revenue immediately. Manufacturing work, sales recruitment and inventory can consume cash before the associated procedures generate receipts. The June financial statements show precisely this phase: a growing commercial effort, small revenue and a product-level loss. Source Source

In this case, European clearance and additional territories broaden the opportunity without instantly changing the income statement. The useful milestones are hospitals completing approval, existing customers reordering and the manufacturing line delivering a lower cost per unit. A promising commercial announcement needs those subsequent steps before it supports a lasting change in the financial outlook.

Bear case

The adverse scenario is that sales coverage and production capacity expand faster than recurring demand. The second quarter of 2026 generated a $643,000 gross loss and a $6.188 million operating loss. If purchasing cycles lengthen, concessions remain necessary or utilization is too low, the cash reserve would increasingly finance an expensive distribution network. Additional equity issuance could then reduce existing holders’ participation before LIBERTY establishes sustainable margins. Source

Regulatory expansion would not resolve weak economics by itself. A clearance opens a market; hospitals still decide whether the workflow justifies adoption. The same applies to distribution agreements: access to institutions is valuable, but it is different from a committed order book. The negative case strengthens if the company reports more opportunities and infrastructure while revenue, collections and gross profit fail to follow.

What Would Falsify This Reading

The constructive reading requires recurring use, improving production economics and sufficient capital to execute the expansion. These observations would weaken it.

• Orders fail to repeat. More territories without sustained use in existing accounts would weaken the adoption thesis described in the August and September 2026 updates. Source Source
• Manufacturing fails to improve. Persistent product losses without a credible path toward the September 2026 target of positive gross margin in 2027 would undermine the economic scale-up. Source Source
• Resources are consumed without progress. Cash use accelerating well beyond the H1 2026 operating average of about $1.674 million monthly, without corresponding commercial progress, would reduce the protection supplied by June liquidity. Source
• Regulatory or clinical execution deteriorates. A material device restriction or a delay beyond the September 2026 European target window would require the commercial schedule and spending assumptions to be reconsidered. Source Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 What LIBERTY sells and what a repeat order means

LIBERTY is a disposable robotic system used to manipulate endovascular instruments during peripheral procedures. Its practical proposition is to let the physician operate away from the immediate radiation field while using a compact system. The FDA record dates its clearance to September 4, 2025; the company announced that clearance on September 8. The current investment question concerns execution after clearance, rather than a hypothetical first FDA decision still ahead. Source Source

A disposable model makes the frequency of procedures particularly important. An initial customer can be encouraging without generating a large recurring contribution. The stronger evidence is sustained ordering as physicians incorporate the system into routine eligible cases. Training, room workflow, compatibility with established practice and hospital economics all influence whether a first use develops into that pattern. Customer counts and procedure activity should therefore be read together whenever the company supplies both.

The July 7, 2026 commercial update confirms the full market release on April 13 and describes expansion from four sales territories at the end of March to eight at the end of June. The August 11 results announcement attributes growth to a mixture of new customers, repeat orders and increased usage. That is a more useful commercial description than a simple list of institutions, although the early revenue base remains small. The next financial evidence must show that these behaviors persist beyond the launch period. Source Source

The business does not become economically attractive merely because it avoids a traditional large robotic-equipment purchase. Disposable systems still require manufacturing, distribution, training and support. Hospitals can face procedural budget constraints even when the initial capital barrier is lower. The company also needs enough recurring volume to spread fixed production and sales costs across a larger number of systems.

The peripheral indication matters when interpreting technology demonstrations. The June 2026 quarterly report discusses remote-operation simulation and exploratory autonomous work. A successful demonstration can inform development, but it does not establish clearance for geographically remote clinical surgery or routine autonomous procedures. Those possibilities are separate from the product and uses supporting the current commercial launch. Source

The FDA indication also defines which potential procedures belong in a current commercial estimate. The clearance expressly excludes coronary and neurointerventional procedures. A presentation about future robotic applications cannot add those markets to the presently cleared sales opportunity. The distinction affects financial analysis: an estimate built from every catheter-based intervention would include procedures that the present label does not cover. Expansion into those applications would require its own development, regulatory and adoption evidence. The initial peripheral business should therefore be judged on its own eligible procedures, purchasing decisions and repeat demand. That is a narrower, testable commercial proposition than treating all future versions of the platform as if hospitals could already order them for routine use. FDA clearance and indication

03 Clinical evidence: an operational result with a defined scope

The April 9, 2025 company report on ACCESS-PVI described twenty patients, successful navigation in every case and no adverse device events during the reported follow-up. It also reported a mean relative reduction of approximately 92% in radiation exposure to the operating physician. These findings support the operational rationale for LIBERTY and formed part of the development history preceding clearance. They are not evidence that every complication in endovascular medicine has been eliminated. Source

The distinction between a device-related event and any adverse event is important. Saying that no adverse device events occurred in the reported sample does not mean that every patient experienced an entirely event-free course, nor does a limited sample establish lifetime safety. The radiation comparison concerns the operator and the reported conditions. It does not necessarily translate into an identical reduction for every person in the room or every future hospital workflow. Source

For commercial adoption, clinical feasibility is necessary but not sufficient. Physicians and hospitals also need predictable preparation, reliable instrument control, staff familiarity and an economic case for using the system. A favorable technical result can coexist with a slow purchasing cycle. Conversely, repeat clinical use can strengthen confidence in the workflow even before revenue is large enough to support the company’s overhead.

The September 25, 2026 growth update reports positive customer feedback and describes efforts to shorten the hospital approval process. That feedback is relevant to commercial execution, but it is not a new controlled clinical outcome study. The earlier twenty-patient ACCESS-PVI sample is separate from a later customer survey with a different purpose. Evidence from the trial and evidence from the sales process answer different questions. Source Source

The clinical question most relevant to the next stage is whether broader real-world use preserves the intended procedural utility and an acceptable safety profile. Any material device problem, regulatory restriction or difficulty integrating the system into routine work could affect reorder behavior. A favorable launch therefore needs continuing evidence from practice as well as the clearance already obtained. The available findings support a defined use case; the commercial thesis depends on executing that use case consistently.

04 The calendar: European clearance, sales coverage and manufacturing

The commercial rollout also involves two named partners. On June 16, 2026, Microbot announced Lovell Government Services as its vendor for access to federal healthcare procurement, including veterans, military and Indian Health Service facilities. Federal Supply Schedule activation was then expected in the third quarter; access to procurement channels is not a guaranteed government order. On June 30 it announced a letter of agreement with Sanmina to manufacture LIBERTY, supporting capacity expansion and cost-reduction objectives. The investment debate also includes White Diamond Research’s May 14 short report, which challenged adoption, procedure economics and reimbursement. Those are the short seller’s claims. Microbot’s May 14 release, filed with the SEC on May 15, disputed misrepresentations and announced a May 18 investor call with executives and physician users, including a surgeon who challenged statements attributed to him. Neither side’s account settles the commercial outcome; repeat utilization, independently assessable clinical results, customer economics and reported revenue remain the tests. Microbot press release (June 16, 2026); Microbot press release (June 30, 2026); White Diamond Research short report; Microbot conference call announcement.

The latest September 25, 2026 update places the expected European CE milestone in late fourth-quarter 2026 or early first-quarter 2027. That is management’s target window, not a fixed approval date or an authorization already received. It is the more recent schedule than the broader second-half expectation discussed in the June quarterly filing. A positive outcome would expand the regulatory opportunity; distribution, customer approvals and initial orders would still determine the financial contribution. Source Source

The same September update targets twelve U.S. sales territories by the end of 2026 and describes the addition of three Area Sales Managers and a Regional Director. Hiring and coverage are leading indicators of the commercial effort, rather than proof of equivalent revenue growth. Their effectiveness depends on converting the pipeline of interested institutions into active accounts and increasing utilization within accounts already opened. Source

The company describes an approximately four-to-six-month hospital approval cycle as of September 25, 2026. That timing explains why commercial investment and reported revenue need not move together each quarter. A hospital still evaluating the system can represent a future opportunity without qualifying as recurring demand. Shortening the process could improve sales productivity, but a delay should not automatically be interpreted as product rejection; the reason for the delay matters. Source

Management also targets positive gross margin during 2027 through production improvements, a second manufacturing line and operating efficiencies, according to the September 25 update. Passing that milestone means that product revenue exceeds the associated product costs. It would not by itself establish operating profitability, because research, sales and administration still need to be funded. The size of the gross profit would matter as much as its sign. Source

These milestones form a sequence rather than one binary event. More territories can create demand; committee approvals can allow use; manufacturing capacity can support shipments; repeated use can generate orders. The quarterly accounts then test whether those steps create margin and cash. A trader following the calendar should distinguish a regulatory decision, a commercial activity announcement and a financial result, because each answers a different part of the investment question.

The four-to-six-month committee interval creates a useful timing illustration. If a new hospital began that process on October 1, an unchanged four-month process would reach approximately February 2027 and a six-month process approximately April 2027. Neither date is a forecast for a particular account. Some institutions could have started earlier, and approval need not be followed immediately by purchasing or regular procedures. This explains why the target of twelve territories at December-end does not equate to twelve equally productive territories throughout the fourth quarter. Comparing mature accounts with newly opened regions would be more informative than dividing one quarter of sales by the year-end territory count and assuming that result represents normal sales productivity.

The commercial follow-up to the May 2026 Israeli clearance, the first marketing authorization for LIBERTY outside the United States, was announced on October 6, 2026. Microbot signed a three-year exclusive agreement with Medtechnica Ltd., an Israeli medical-device distributor, to market and sell LIBERTY in Israel. The release says the system received approval from the Israeli Ministry of Health’s AMAR division and was registered in the national medical-device registry in May 2026, and that the company anticipates initial orders from Medtechnica in the fourth quarter of 2026. It discloses no financial terms, minimum volumes or expected order values, so the agreement does not yet provide a basis for estimating revenue. In Merlintrader’s reading, the Israeli market is small compared with the U.S. and European opportunity; the agreement matters mainly as an early test of the distributor model the company says it intends to repeat in other developed markets, while the European CE milestone remains the larger regulatory checkpoint. Source

05 Revenue: strong sequential growth from a small base

Second-quarter 2026 revenue was $241,000, compared with a calculated $105,000 in the first quarter, derived from first-half revenue of $346,000. The resulting sequential growth was approximately 129.5%. That is a substantial relative improvement, but the absolute sales level remains early stage. The dollar increase was $136,000, which helps put the percentage in the context of the company’s operating costs. Source

The August 11, 2026 announcement attributes commercial progress to new accounts, repeat purchases and greater use. Repeat purchases are particularly relevant for a disposable system because they can indicate adoption beyond an initial evaluation. The statement nevertheless does not make all future usage predictable. The next accounts should show whether sales develop across successive periods and whether the customer base becomes less dependent on a small number of enthusiastic early adopters. Source

Quarterly growth can be uneven while hospital approvals and training are still developing. A shipment to a new account can affect one quarter before the frequency of later orders is clear. Comparing revenue with receivables and inventory helps determine whether reported growth is accompanied by collection and orderly stock management. It also avoids treating an increase in product availability as if it were already end-user demand.

The June 30, 2026 balance sheet reports inventory of $2.907 million, up from $584,000 at December 31, 2025. Building stock can be appropriate ahead of a launch, especially when the company needs reliable supply for demonstrations and customer orders. It also commits cash before the sales outcome is known. A successful launch should eventually produce a better relationship between inventory held, systems delivered and repeat demand. Source

The next useful revenue comparison is therefore broader than whether the reported percentage looks large. It includes the absolute sales gain, its persistence, the contribution from existing customers and the resources needed to obtain it. If revenue grows while cash consumption and inventory rise much faster, the commercial trajectory may still be improving, but the financing burden has also increased. The stronger pattern is one in which each expansion of sales increasingly supports its own production and distribution costs.

Inventory increased by $2.323 million during the first half, almost four times the $584,000 opening balance and about 6.7 times first-half revenue of $346,000. These are comparisons of scale, not inventory-turnover measures: inventory is carried at cost while revenue reflects selling prices, and the launch is changing both volumes and production costs. The calculation does not prove excess stock or obsolescence. It does show that the manufacturing commitment was substantially larger than sales recognized during the same period. A subsequent increase in orders could absorb that investment; slower demand could leave more working capital tied up. Product costs, inventory changes and the reasons management gives for each need to be read together before diagnosing whether stock accumulation is helping or delaying the commercial transition.

06 Margins: the main test behind the growth headline

For the quarter ended June 30, 2026, product costs were $884,000 against $241,000 of revenue, producing a $643,000 gross loss. This is the central limitation of the current commercial result. More revenue can improve the economics as volume increases, but the reported quarter does not yet demonstrate that the product generates a positive contribution before research and corporate expenses. Source

The comparison with the first quarter needs care. The June 2026 report explains that certain units sold earlier had been manufactured before clearance and their costs had previously been charged to research and development. The second quarter also reflected higher manufacturing labor costs and concessions to customers. The small first-quarter gross profit implied by the half-year figures therefore is not a clean benchmark for a mature production margin. Source

Manufacturing improvements can address part of the problem. Higher throughput may spread production overhead more effectively, while process improvements can reduce labor and other costs. Pricing and customer concessions matter too. A margin improvement obtained only by reducing introductory discounts would have a different explanation from one driven by cheaper and more efficient production. Both can help, but they have different implications for the durability of the result.

Second-quarter 2026 selling, general and administrative expense reached $3.684 million, compared with $1.612 million a year earlier, as the commercial organization expanded. Research and development expense was $1.861 million, versus $2.111 million. The filing links the latter change partly to grants and the treatment of manufacturing expenditure as inventory; it does not mean development activity simply ended. Operating loss was $6.188 million for the quarter. Source

The September 2026 target of positive gross margin during 2027 is therefore an intermediate milestone. Even after crossing it, gross profit must become large enough to support the rest of the organization. Until then, investment in sales can increase the cash burden before its benefits appear. The constructive reading needs evidence that management can improve the production economics while keeping the commercial expansion productive, rather than treating growth and cost discipline as unrelated objectives. Source

The reported gross margin was approximately minus 266.8%, calculated as the $643,000 gross loss divided by $241,000 of revenue. Put another way, reported product costs were about 3.67 times sales. At unchanged quarterly product costs of $884,000, arithmetic product break-even would require that same $884,000 of revenue, approximately 267% above the second-quarter level. This is a deliberately static illustration, not a sales target or forecast: costs would change with units, production efficiency and commercial concessions. It makes the size of the current gap visible while preventing a misleading inference that simply repeating the previous sequential growth percentage would guarantee a profitable product quarter.

A separate operating illustration starts from quarterly research expense of $1.861 million and selling, general and administrative expense of $3.684 million, a combined $5.545 million. At an assumed future gross margin of 50%, approximately $11.09 million of quarterly revenue would be needed to cover that unchanged expense base before financing income and taxes. At an assumed 30% margin, the equivalent would be about $18.48 million. Neither margin is company guidance, and overhead could grow or fall. These scenarios are not a valuation model. They show why crossing from negative to slightly positive gross margin, although meaningful, is economically different from generating enough gross profit to sustain the entire organization.

07 Cash, monthly burn and the difference between arithmetic and guidance

At June 30, 2026, Microbot held $3.152 million of cash and cash equivalents and $64.215 million of marketable securities invested in money-market funds. Their calculated sum is $67.367 million of unrestricted resources. Restricted cash of $263,000 and a restricted deposit of $814,000 are separate and are excluded from that total. The comparable free cash-and-securities total at December 31, 2025 was $78.592 million. Source

First-half 2026 operating cash use was $10.042 million. Dividing by six gives a calculated historical burn of approximately $1.674 million a month. Dividing June unrestricted resources by that average gives approximately 40.3 months of static coverage. This is a comparison of a dated balance with a historical rate, not management guidance or a forecast of the month when cash runs out. Commercial recruitment, manufacturing and utilization can change the spending pattern substantially. Source

The company’s August 11, 2026 quarterly filing states that available cash and investments should fund operations for more than twelve months from issuance of the statements. That is the management statement to keep separate from the longer mechanical calculation. The filing does not turn the historical quotient into a fixed long-range operating budget. Source

Capital expenditure was $250,000 in the first half of 2026. Adding it to operating use gives $10.292 million, or a calculated $1.715 million per month. The difference is modest for that period, but it identifies another use of resources. The operating cash flow also includes $2.323 million absorbed by inventory and $176,000 by receivables, partly offset by increases in operating liabilities. Cash consumption reflects the launch’s working-capital needs as well as the income-statement loss. Source

The small cash-account balance should not be considered in isolation from the money-market securities, which make up most of the liquid resources. Equally, redemptions of investments can maintain the bank balance while total liquidity declines. The relevant comparison follows both categories together and preserves restricted amounts separately. The balance gives the company room to execute, but that room is finite and should be evaluated against progress in revenue and gross profit, not only the passage of time.

A cash sensitivity can be calculated without pretending to know the next spending plan. Raising the historical operating-use rate by 25% gives approximately $2.092 million monthly and 32.2 months of coverage against the June balance; a 50% increase gives approximately $2.511 million and 26.8 months. Both are illustrative quotients measured from the dated June resource base, not remaining runway as of October. They exclude subsequent cash flows, future financing and separate capital expenditure. The difference from the 40.3-month historical quotient shows that a sizable cash balance does not remove sensitivity to commercialization costs. It also shows why management can use a cautious funding statement of more than one year without endorsing a much longer numerical projection.

The operating cash-flow bridge explains why net loss alone understates first-half resource use. Starting with the $9.298 million net loss, adding $655,000 of noncash compensation and $27,000 of depreciation, and removing $215,000 of investment-related income and gains gives a subtotal cash outflow of $8.831 million. Receivables and inventory absorbed a further $2.499 million; changes in prepaid expenses and other assets supplied $69,000, while payables and accruals supplied $1.219 million. The result is the reported $10.042 million operating outflow. Those liability increases finance part of the launch temporarily and need not recur. A later quarter could therefore show a different relationship between reported loss and cash consumption even with a similar level of sales.

08 Financing capacity and obligations attached to growth

The June 2026 report describes an ATM prospectus supplement dated April 10 with an offering maximum of approximately $39.231 million. On April 15, the company sold 6,757 shares for gross proceeds of $17,021 and net proceeds of $16,240. The program is potential issuance capacity, not cash already sitting beside the June balance. The amount actually raised in that transaction was small, but its existence means it would be incorrect to describe the first half as having no share issuance. Source

An ATM can provide flexibility if the company decides to sell shares over time. The proceeds depend on prices, demand, applicable terms and how much stock is issued. A higher authorized amount does not guarantee attractive economics for existing holders. Financing becomes more consequential if the commercial ramp takes longer or consumes more capital than management anticipates.

The June 30, 2026 balance sheet reports operating lease liabilities totaling $876,000, combining current and longer-term amounts. Commercialization also carries contingent royalty obligations. The quarterly report describes Israel Innovation Authority support with royalties generally linked to relevant sales, and separate licensing arrangements involving the underlying technology. These obligations are not equivalent to a conventional principal balance immediately due, but they can affect the portion of future revenue retained by Microbot. Source

The product and agreement scope matter when considering royalties. The June filing describes different bases and rates for government support, licensed technology and assets acquired from other parties. The stated rates do not all apply to every dollar of LIBERTY revenue. The financially relevant question is which obligations apply to the actual product sold and how those payments interact with gross-margin improvement. Source

The July 28, 2026 Forge Medical asset acquisition adds VasoStat-related assets with potential future royalty consideration capped at $5 million, as disclosed in the August quarterly report. That is not a $5 million upfront cash payment or an immediate new revenue stream. The agreement includes commercialization-effort conditions and potential return of assets if required launches do not occur within the contractual periods. The opportunity must therefore be judged against development effort, product readiness and eventual sales, rather than the maximum contingent payment alone. Source

09 Shares, warrants and employee awards

Microbot reported 67,164,801 common shares outstanding at June 30, 2026 and the same number on the August 11 cover date, compared with 67,158,044 at year-end 2025. The June report lists 120 million common shares and one million preferred shares authorized. Authorized stock is a legal capacity for potential issuance, not a statement that all those shares are already outstanding or will necessarily be issued. Source

Warrants outstanding at June 30, 2026 covered 16,284,888 shares. Of these, 13,989,115 were Series J warrants with a $4.50 exercise price and expirations in March and April 2028. The remaining warrants were placement-agent instruments with different exercise prices and expirations. These categories are separate from the older warrants already exercised during the 2025 financing transactions; combining them would count the same capital history twice. Source

The Series J exercise price was well above the $1.20 reference close on October 1, 2026. That comparison helps explain why possible exercise proceeds are not assured near-term funding. Warrants can increase share supply if exercised, while cashless provisions and other contractual terms can also affect the economics. Their existence is a dilution exposure, not an obligation for holders to finance the company. Source Source

The annual report records 3,105,615 employee and director options outstanding at December 31, 2025, with a weighted-average exercise price of $4.18. The June 2026 report describes 1,127,500 options granted in the first half, including awards to the chief executive, employees and directors. Adding those awards mechanically to the year-end balance would not establish a verified current option total without accounting for exercises, expirations and forfeitures. The dated figures nevertheless show that compensation is another route to future issuance. Source Source

For existing holders, the important comparison is progress per share after financing and compensation, not solely progress for the company in aggregate. The cash reserve can support the business while outstanding and potential shares influence how much of eventual success belongs to each holder. These are related questions, and neither the warrant count nor the authorized share ceiling supplies a price target by itself.

A limited warrant illustration adds only the 13,989,115 Series J underlying shares to the dated basic count of 67,164,801. The resulting denominator is 81,153,916 shares. The original common block would represent approximately 82.8% of that total, assuming those holders did not also own the warrants. Full cash exercise at $4.50 would provide approximately $62.951 million gross before any applicable costs. This is not a fully diluted current share count, because it excludes other warrants, employee awards and later transactions. It is also not expected financing at the October 1 reference price of $1.20. The calculation places the potential capital contribution beside its ownership consequence instead of presenting the proceeds as free funding or the dilution as an event already completed.

10 Ownership, insider transactions and short positioning

Finviz data as of October 2, 2026 report a float of approximately 61.03 million shares, short interest equal to 11.59% of that float and a short ratio of 11.26. The underlying settlement date is not stated, so these are dated third-party figures; they do not mean all positions were established that day. The same data report insider ownership of 9.14% and institutional ownership of 17.26%. The reference closing price is $1.20 on October 1, 2026. Source

The short ratio depends on the trading activity used in its calculation. It is not a countdown to compulsory covering and does not establish that a squeeze must occur. Positioning can amplify a response to commercial or regulatory information, but the information itself and the available share supply remain central. An event with no improvement in adoption or economics may leave the fundamental debate unchanged even if trading is volatile.

Intracoastal’s January 23, 2026 ownership filing reports beneficial ownership of 6,002,185 shares, or 8.2%, through warrant-underlying shares. That is not a block consisting entirely of already issued common stock. The related reporting persons describe interests in the same position; they are not independent holdings. This filing illustrates why beneficial ownership, current voting stock and a third-party data service’s institutional percentage can answer different questions. Source

Recent director filings also need classification. The April 1, 2026 transactions reported for Martin Madden, Tal Wenderow and Aileen Stockburger were grants of 10,000 options each at a $2.37 exercise price. They were compensation awards, not purchases of common stock with personal cash in the open market. The awards create exposure to future share value, but they do not provide the same evidence as an insider choosing to buy shares. Source Source Source

The useful ownership picture combines these distinctions with the financing instruments already described. A large beneficial-interest number can include exercisable securities; a new insider award can be compensation; and a short percentage can be a lagged snapshot. Keeping those categories separate makes the trading context more informative without turning it into a substitute for the commercial evidence.

The Intracoastal percentage comes directly from the filing rather than from a third-party float figure. The disclosed 6,002,185 warrant-underlying shares divided by 67,158,044 previously outstanding common shares plus those same underlying shares gives approximately 8.2%. Dividing by basic shares alone would give approximately 8.9%, a different denominator from the one the filing uses. Repeating the 6,002,185 figure for each related reporting person would compound the error by counting the same position more than once. This example also shows that the percentage is not a new independent slice of ownership on top of third-party institutional figures. The document is a dated beneficial-interest disclosure, not a clean partition of all issued shares or proof that the warrants were subsequently exercised.

11 Red flags, the next accounts and the investment conclusion

The immediate operating red flags are persistent negative product margins, slower-than-expected hospital approvals, inventory growing faster than usage and commercial costs expanding without corresponding orders. The June 2026 results show that these are practical sensitivities rather than abstract risks: the company is investing ahead of revenue and still absorbs cash. Its liquidity gives it time to learn, but does not make every commercial expansion economically productive. Source

For the European milestone, the question is whether the anticipated late-2026 or early-2027 clearance arrives and which commercial steps follow. The September 25, 2026 target is conditional. An approval would be positive for access, while a delay would require an updated schedule and an assessment of costs. Neither outcome translates automatically into a particular revenue figure without evidence of ordering and deployment. Source

The next financial report should make the relationship between sales, product costs and cash easier to assess. Revenue growth accompanied by improving gross economics and repeat orders would strengthen the favorable scenario. Growth obtained through continuing concessions, a larger inventory build and rising overhead would offer a less convincing path. The same revenue total can carry a different meaning depending on what it cost to achieve and whether customers return.

Management’s 2027 positive-gross-margin objective is a useful intermediate test, as stated on September 25, 2026. Passing it would show progress toward a functioning product business. The later question is whether the resulting gross profit can cover the commercial organization and continued development. Treating the first milestone as complete company profitability would skip the central remaining financial work. Source

The overall reading is an already commercial medical-device company with meaningful resources and an unproven economic scale. LIBERTY’s regulatory clearance and early repeat orders establish a starting point. The investment case improves when those orders become sustained usage, production becomes more efficient and the expansion consumes less capital for each increment of revenue. The cash balance, warrant exposure and ATM capacity define the resources and potential dilution along that path. The decisive evidence will come from adoption and the accounts together, rather than from a single launch headline.